Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Homeobox protein HMX1 is a DNA-binding transcription factor that binds the 5'-CAAG-3' DNA core sequence and primarily acts as a transcriptional repressor[1][5]. It is integral to the development and patterning of craniofacial features and ocular structures, functioning in regions such as the retina, cranial ganglia, and craniofacial mesenchyme during vertebrate embryogenesis[1][4]. Mutations in HMX1 cause rare syndromic disorders that include eye and ear developmental defects, demonstrating its central regulatory role in morphogenesis[1][4][5]. Its molecular activity depends on dimerization via its homeodomain and adjacent SD1 domain, enabling it to modulate expression of genes critical for neuron development and retinal organization[1][3][4]. There is no evidence to support direct pharmacological targeting or use as a diagnostic biomarker in current clinical practice[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Homeobox protein HMX1 (HMX1).